Combined General Meeting of April 2, 2024 Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, will hold…
Biophytis announces the implementation of a reverse stock split of its ordinary shares traded on Euronext Growth Biophytis announces that it has decided to implement a reverse stock split, with effect from April 2 2024, on the basis of 1 new share for every 400 held. Fullscreen Mode
Biophytis announces its participation in several events in Europe and the United States over the coming months Biophytis outcomes for patients suffering from age-related diseases, has announced its participation in several conferences until the end of the first half of 2024. Annual scientific conference on sarcopenia Biophytis management will take part in the 14th International…
Biophytis presented the potential of Ruvembri™ in the treatment of Duchenne Muscular Dystrophy Biophytis presented the results of its recent clinical trials with Ruvembri™ at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, held from 3 to 6 March 2024 in Orlando, USA. Administered orally, Ruvembri™ activates the MAS receptor, stimulating respiratory and motor…
“Live healthier longer” – Publication of a book on the medicine and science of longevity Biophytis announces the publication of a book written by Stanislas Veillet, CEO and co- founder of the company, together with René Lafont, Professor Emeritus at Sorbonne University and co- founder of Biophytis, and Jean Mariani, Professor and Director of the…
Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet Biophytis announces the publication of an article on the results of its COVA phase 2-3 clinical trial in the treatment of respiratory symptoms in severe forms of COVID-19 in eClinicalMedicine, a medical journal part of the…
Biophytis announces the drawing of the fourth tranche of ORNANE under the 2021 Atlas Contract Biophytis announces the drawing of a new tranche of Bonds Redeemable in Cash and New and Existing Shares (ORNANE) under its existing convertible bond agreement with Atlas, a specialized investment fund based in New York (United States). Fullscreen Mode
Biophytis announces its participation in several conferences in Europe and the US during the first quarter of 2024 Biophytis management will be in San Francisco for meetings with potential partners and investors at the 42nd JP Morgan Healthcare Conference, to be held from 8 to 11 January 2024. In addition, the company will be present:…
Biophytis and the University of Liège explore the potential of Sarconeos (BIO101) in the treatment of viral respiratory failure Biophytis announces the signing of a new partnership with the University of Liège to carry out a range of preclinical research projects, particularly in the treatment of respiratory failure caused by the flu virus Influenza. Under…
Biophytis appoints Yann Meunier and Bernard Lévy to its Scientific Advisory Board Biophytis announced the appointment of Dr Yann Meunier and Professor Bernard Lévy to its Scientific Advisory Board. Yann Meunier is a US-based healthcare professional, currently Professor and Director of the International Institute of Medicine and Science, Inc (IIMS), where he leads the development…